Clinical evaluation of twice-daily emedastine 0.05% eye drops (emadine eye drops) versus levocabastine 0.05% eye drops in patients with allergic conjunctivitis

Ph Verin, D. L. Easty, A. Secchi, G. Ciprandi, P. Partouche, G. Nemeth-Wasmer, R. Brancato, C. J. Harrisberg, C. Estivin-Ebrardt, D. J. Coster, A. J G Apel, M. T. Coroneo, M. Knorr, T. R. Carmichael, B. T. Kent-Smith, P. Abrantes, A. Leonardi, P. M. Cerqueti, G. Modorati, M. Martinez

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

• PURPOSE: The efficacy and safety of emedastine 0.05% eye drops (Emadine; Alcon Laboratories, Inc, Fort Worth, Texas), a new H1 antagonist, were studied in comparison to levocabastine 0.05% eye drops (Livostin; Janssen-Cilag N V, Berchem, Belgium) during a twice-daily treatment schedule for 6 weeks in adult and pediatric patients with seasonal allergic conjunctivitis. • METHODS: In a prospective, multicenter, randomized, double-masked, parallel group study, 222 patients with allergic conjunctivitis were randomized (221 received treatment) to either emedastine or levocabastine, instilled twice daily for 6 weeks. Patient diaries were completed four times daily (before the morning and evening instillations, at noon, and in the afternoon), and clinical examinations were conducted at regular intervals. Primary efficacy variables of ocular redness and itching and secondary efficacy variables of chemosis, eyelid swelling, patient diary data, and physician's global assessment were analyzed. • RESULTS: Both emedastine and levocabastine produced a statistically significant (P = .0001) reduction in itching and redness within 5 minutes of the first instillation. All signs and symptoms improved progressively over the 6-week treatment period. After 7 days of use, and throughout the remainder of the study, emedastine was statistically superior to levocabastine (P <.006) in preventing and alleviating the signs and symptoms (itching, redness, chemosis, and eyelid swelling) of allergic conjunctivitis. • CONCLUSIONS: Emedastine 0.05% eye drops administered twice daily are more efficacious than levocabastine 0.05% eye drops in the prevention and treatment of the signs and symptoms of allergic conjunctivitis in adults and children of 4 years and above. Both emedastine 0.05% eye drops and levocabastine 0.05% eye drops were well tolerated.

Original languageEnglish
Pages (from-to)691-698
Number of pages8
JournalAmerican Journal of Ophthalmology
Volume131
Issue number6
DOIs
Publication statusPublished - 2001

Fingerprint

emedastine
levocabastine
Allergic Conjunctivitis
Ophthalmic Solutions
Pruritus
Signs and Symptoms
Eyelids
Belgium
Therapeutics
Appointments and Schedules

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Clinical evaluation of twice-daily emedastine 0.05% eye drops (emadine eye drops) versus levocabastine 0.05% eye drops in patients with allergic conjunctivitis. / Verin, Ph; Easty, D. L.; Secchi, A.; Ciprandi, G.; Partouche, P.; Nemeth-Wasmer, G.; Brancato, R.; Harrisberg, C. J.; Estivin-Ebrardt, C.; Coster, D. J.; Apel, A. J G; Coroneo, M. T.; Knorr, M.; Carmichael, T. R.; Kent-Smith, B. T.; Abrantes, P.; Leonardi, A.; Cerqueti, P. M.; Modorati, G.; Martinez, M.

In: American Journal of Ophthalmology, Vol. 131, No. 6, 2001, p. 691-698.

Research output: Contribution to journalArticle

Verin, P, Easty, DL, Secchi, A, Ciprandi, G, Partouche, P, Nemeth-Wasmer, G, Brancato, R, Harrisberg, CJ, Estivin-Ebrardt, C, Coster, DJ, Apel, AJG, Coroneo, MT, Knorr, M, Carmichael, TR, Kent-Smith, BT, Abrantes, P, Leonardi, A, Cerqueti, PM, Modorati, G & Martinez, M 2001, 'Clinical evaluation of twice-daily emedastine 0.05% eye drops (emadine eye drops) versus levocabastine 0.05% eye drops in patients with allergic conjunctivitis', American Journal of Ophthalmology, vol. 131, no. 6, pp. 691-698. https://doi.org/10.1016/S0002-9394(00)00947-8
Verin, Ph ; Easty, D. L. ; Secchi, A. ; Ciprandi, G. ; Partouche, P. ; Nemeth-Wasmer, G. ; Brancato, R. ; Harrisberg, C. J. ; Estivin-Ebrardt, C. ; Coster, D. J. ; Apel, A. J G ; Coroneo, M. T. ; Knorr, M. ; Carmichael, T. R. ; Kent-Smith, B. T. ; Abrantes, P. ; Leonardi, A. ; Cerqueti, P. M. ; Modorati, G. ; Martinez, M. / Clinical evaluation of twice-daily emedastine 0.05% eye drops (emadine eye drops) versus levocabastine 0.05% eye drops in patients with allergic conjunctivitis. In: American Journal of Ophthalmology. 2001 ; Vol. 131, No. 6. pp. 691-698.
@article{10a36228aa654df1a95170467116333b,
title = "Clinical evaluation of twice-daily emedastine 0.05{\%} eye drops (emadine eye drops) versus levocabastine 0.05{\%} eye drops in patients with allergic conjunctivitis",
abstract = "• PURPOSE: The efficacy and safety of emedastine 0.05{\%} eye drops (Emadine; Alcon Laboratories, Inc, Fort Worth, Texas), a new H1 antagonist, were studied in comparison to levocabastine 0.05{\%} eye drops (Livostin; Janssen-Cilag N V, Berchem, Belgium) during a twice-daily treatment schedule for 6 weeks in adult and pediatric patients with seasonal allergic conjunctivitis. • METHODS: In a prospective, multicenter, randomized, double-masked, parallel group study, 222 patients with allergic conjunctivitis were randomized (221 received treatment) to either emedastine or levocabastine, instilled twice daily for 6 weeks. Patient diaries were completed four times daily (before the morning and evening instillations, at noon, and in the afternoon), and clinical examinations were conducted at regular intervals. Primary efficacy variables of ocular redness and itching and secondary efficacy variables of chemosis, eyelid swelling, patient diary data, and physician's global assessment were analyzed. • RESULTS: Both emedastine and levocabastine produced a statistically significant (P = .0001) reduction in itching and redness within 5 minutes of the first instillation. All signs and symptoms improved progressively over the 6-week treatment period. After 7 days of use, and throughout the remainder of the study, emedastine was statistically superior to levocabastine (P <.006) in preventing and alleviating the signs and symptoms (itching, redness, chemosis, and eyelid swelling) of allergic conjunctivitis. • CONCLUSIONS: Emedastine 0.05{\%} eye drops administered twice daily are more efficacious than levocabastine 0.05{\%} eye drops in the prevention and treatment of the signs and symptoms of allergic conjunctivitis in adults and children of 4 years and above. Both emedastine 0.05{\%} eye drops and levocabastine 0.05{\%} eye drops were well tolerated.",
author = "Ph Verin and Easty, {D. L.} and A. Secchi and G. Ciprandi and P. Partouche and G. Nemeth-Wasmer and R. Brancato and Harrisberg, {C. J.} and C. Estivin-Ebrardt and Coster, {D. J.} and Apel, {A. J G} and Coroneo, {M. T.} and M. Knorr and Carmichael, {T. R.} and Kent-Smith, {B. T.} and P. Abrantes and A. Leonardi and Cerqueti, {P. M.} and G. Modorati and M. Martinez",
year = "2001",
doi = "10.1016/S0002-9394(00)00947-8",
language = "English",
volume = "131",
pages = "691--698",
journal = "American Journal of Ophthalmology",
issn = "0002-9394",
publisher = "Elsevier USA",
number = "6",

}

TY - JOUR

T1 - Clinical evaluation of twice-daily emedastine 0.05% eye drops (emadine eye drops) versus levocabastine 0.05% eye drops in patients with allergic conjunctivitis

AU - Verin, Ph

AU - Easty, D. L.

AU - Secchi, A.

AU - Ciprandi, G.

AU - Partouche, P.

AU - Nemeth-Wasmer, G.

AU - Brancato, R.

AU - Harrisberg, C. J.

AU - Estivin-Ebrardt, C.

AU - Coster, D. J.

AU - Apel, A. J G

AU - Coroneo, M. T.

AU - Knorr, M.

AU - Carmichael, T. R.

AU - Kent-Smith, B. T.

AU - Abrantes, P.

AU - Leonardi, A.

AU - Cerqueti, P. M.

AU - Modorati, G.

AU - Martinez, M.

PY - 2001

Y1 - 2001

N2 - • PURPOSE: The efficacy and safety of emedastine 0.05% eye drops (Emadine; Alcon Laboratories, Inc, Fort Worth, Texas), a new H1 antagonist, were studied in comparison to levocabastine 0.05% eye drops (Livostin; Janssen-Cilag N V, Berchem, Belgium) during a twice-daily treatment schedule for 6 weeks in adult and pediatric patients with seasonal allergic conjunctivitis. • METHODS: In a prospective, multicenter, randomized, double-masked, parallel group study, 222 patients with allergic conjunctivitis were randomized (221 received treatment) to either emedastine or levocabastine, instilled twice daily for 6 weeks. Patient diaries were completed four times daily (before the morning and evening instillations, at noon, and in the afternoon), and clinical examinations were conducted at regular intervals. Primary efficacy variables of ocular redness and itching and secondary efficacy variables of chemosis, eyelid swelling, patient diary data, and physician's global assessment were analyzed. • RESULTS: Both emedastine and levocabastine produced a statistically significant (P = .0001) reduction in itching and redness within 5 minutes of the first instillation. All signs and symptoms improved progressively over the 6-week treatment period. After 7 days of use, and throughout the remainder of the study, emedastine was statistically superior to levocabastine (P <.006) in preventing and alleviating the signs and symptoms (itching, redness, chemosis, and eyelid swelling) of allergic conjunctivitis. • CONCLUSIONS: Emedastine 0.05% eye drops administered twice daily are more efficacious than levocabastine 0.05% eye drops in the prevention and treatment of the signs and symptoms of allergic conjunctivitis in adults and children of 4 years and above. Both emedastine 0.05% eye drops and levocabastine 0.05% eye drops were well tolerated.

AB - • PURPOSE: The efficacy and safety of emedastine 0.05% eye drops (Emadine; Alcon Laboratories, Inc, Fort Worth, Texas), a new H1 antagonist, were studied in comparison to levocabastine 0.05% eye drops (Livostin; Janssen-Cilag N V, Berchem, Belgium) during a twice-daily treatment schedule for 6 weeks in adult and pediatric patients with seasonal allergic conjunctivitis. • METHODS: In a prospective, multicenter, randomized, double-masked, parallel group study, 222 patients with allergic conjunctivitis were randomized (221 received treatment) to either emedastine or levocabastine, instilled twice daily for 6 weeks. Patient diaries were completed four times daily (before the morning and evening instillations, at noon, and in the afternoon), and clinical examinations were conducted at regular intervals. Primary efficacy variables of ocular redness and itching and secondary efficacy variables of chemosis, eyelid swelling, patient diary data, and physician's global assessment were analyzed. • RESULTS: Both emedastine and levocabastine produced a statistically significant (P = .0001) reduction in itching and redness within 5 minutes of the first instillation. All signs and symptoms improved progressively over the 6-week treatment period. After 7 days of use, and throughout the remainder of the study, emedastine was statistically superior to levocabastine (P <.006) in preventing and alleviating the signs and symptoms (itching, redness, chemosis, and eyelid swelling) of allergic conjunctivitis. • CONCLUSIONS: Emedastine 0.05% eye drops administered twice daily are more efficacious than levocabastine 0.05% eye drops in the prevention and treatment of the signs and symptoms of allergic conjunctivitis in adults and children of 4 years and above. Both emedastine 0.05% eye drops and levocabastine 0.05% eye drops were well tolerated.

UR - http://www.scopus.com/inward/record.url?scp=0035013968&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035013968&partnerID=8YFLogxK

U2 - 10.1016/S0002-9394(00)00947-8

DO - 10.1016/S0002-9394(00)00947-8

M3 - Article

C2 - 11384563

AN - SCOPUS:0035013968

VL - 131

SP - 691

EP - 698

JO - American Journal of Ophthalmology

JF - American Journal of Ophthalmology

SN - 0002-9394

IS - 6

ER -